News center

Thank you for your interest in HUIZHONG

News center
General Search
keyword :

Your present location:Home >> News center >> Main content
Main content

NVC has made significant progress in the NADC30 PRRSV study

Number of visits: Date:2017-08-01 11:56:49

Abstract:

On June 4, 2017, the 14th International Nested Virus Conference was successfully held in Kansas, USA. The International Nested Virus Conference is held every two years. The participants are mainly from academia and internationally renowned enterprises. The number of participants in this conference is about 1,200 people.

On June 4, 2017, the 14th International Nested Virus Conference was successfully held in Kansas, USA. The International Nested Virus Conference is held every two years. The participants are mainly from academia and internationally renowned enterprises. The number of participants in this conference is about 1,200 people.

Dr. Bai Chengzhong, Vice Chairman of NVC, Dr. Tian Kegong, Director of NVC, Dr. Li Xiuling, Assistant Director of the Center, Dr. Li Xiangdong, Director of Bioengineering Research Institute, and Kang Buli, General Manager of Pulike Seedling Division, were invited to attend the 14th International Docking Virus Conference.

At the meeting, Dr. Tian Kegong, Director of NVC, gave a lecture on "Development and Application of PRRSV vaccine development and application in China". In his report, Dr. Tian introduced the development of the JXA1-PRRSV vaccine and the research work on the NADC30 PRRSV at the National Veterinary Drug Engineering Technology Research Center (Nvc).

The NADC30 PRRSV (NADC30-like PRRSV) was named the NADC30 PRRSV strain because the genome of the virus was closest to that of the 2008 NADC30 PRRSV strain. In 2012, China for the first time isolated class NADC30 PRRSV, the virus has been popular in most provinces in China. In contrast to previous PRRSV strains, the virus and other viral recombination rates were significantly improved, the virulence of the strains was quite different, and the commercialization of PRRSV vaccine was limited. Therefore, NADC30 PRRSV brought huge Economic losses.

In recent years, NVC has carried out systematic basic research on the genome characteristics, epidemic range, pathogenicity and commercial protection of NADC30 PRRSV in our country, and has produced a wide range of international impact. The concrete results are as follows:

1. Isolate more than 40 strains of virus
2. Application for national invention patent 3
3. published "pig breeding and respiratory syndrome" monograph 1
4. published SCI papers 7:

① Li C, et al. Transbound Emerg Dis. 2016 Oct; 63 (5): 474-9.
② Li X, et al. Springerplus. 2016 Sep 29; 5 (1): 1677.
③ Sun Z, et al. Arch Virol. 2016 Aug; 161 (8): 2257-61.
④ Bai X, et al. Vaccine. 2016 Nov 4; 34 (46): 5540-554Li5.
⑤ Li X, et al. Infect Genet Evol. 2016 Dec 22. pii: S1567-1348 (16) 30550-0.
⑥ Ji G, et al. Genome Announc. 2016 Apr 21; 4 (2). Pii: e00303-16.
⑦ Li Y, et al. Genome Announc. 2016 May 5; 4 (3). Pii: e00330-16.
 
After years of innovation and practice, Pulike in all kinds of innovative platform construction and technology research and development to achieve the international standards, the relevant technical achievements reached the leading domestic and international advanced level, and have complete conditions of research and development and engineering, industrial conditions. Was invited to attend the 14th International Docking Virus Conference and delivered a keynote report, which attracted the attention of Pulco and NVC, and greatly enhanced the popularity of Pulike and NVC in the field of international dynamic maintenance.

TypeInfo: Company news

Keywords for the information:

Email: export@huizhongsy.com.cn Tel: +86 0379-61123578
Add: No.15 Zhenghe Road, Luolong District, Luoyang City, Henan Province
豫ICP备11017935号 TECHNICAL SUPPORT BY YICHANG.300.CN